872993-05-0

872993-05-0 structure

Name: Resolvin D1
Chemical Name: 7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
CAS Number: 872993-05-0
Molecular Formula: C₂₂H₃₂O₅
Molecular Weight: 376.487
Catalog: Research Areas Inflammation/Immunology
Create Date: 2017-07-22 09:39:39
Modify Date: 2025-08-27 13:40:48
Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].

Name	7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
Synonyms	(4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-7,8,17-Trihydroxy-4,9,11,13,15,19-docosahexaenoic acid 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid 4,9,11,13,15,19-Docosahexaenoic acid, 7,8,17-trihydroxy-, (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)- Resolvin D1 17(R)-Resolvin D1

Description	Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].
Related Catalog	Research Areas >> Inflammation/Immunology
Target	Human Endogenous Metabolite
In Vitro	Resolvin D1 (RvD1) (1-100 nM; 15 minutes) induces dose-dependent short-term functional changes in primary human macrophages. RvD1 triggers intracellular Ca2+ release, blocks chemotactic migration, and stimulates phagocytosis of microbial particles with maximal efficiency at 10 nM[1].Resolvin D1 (0-500 nM; 72 hours) shows a strong inhibition of LPS-induced TRAP and cathepsin K expression by RvD1 at different concentrations in RAW264.7 macrophages[2].
In Vivo	Resolvin D1 (RvD1) (100-1000 ng; i.p.; daily on days 10) improves RA (rheumatoid arthritis) clinical endpoints in arthritic mice[3]. Animal Model: 18-20 g thirty 8-week-old female DBA/1J mice (collagen antibody-induced arthritis (CAIA))[3] Dosage: 100, 500, and 1000 ng (or 1000 ng, daily on days 4-10) Administration: i.p. injection; daily on days 10 Result: Exhibit a reduced arthritic score.
References	[1]. Schmid M, et al. Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32. J Immunol. 2016 Apr 15;196(8):3429-37. [2]. Gao Y, et al. Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome. J Immunol. 2017 Aug 9. pii: ji1700315. [3]. Benabdoun HA, et al. In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. Arthritis Res Ther. 2019 Mar 12;21(1):72.

Density	1.1±0.1 g/cm3
Boiling Point	609.2±55.0 °C at 760 mmHg
Molecular Formula	C₂₂H₃₂O₅
Molecular Weight	376.487
Flash Point	336.3±28.0 °C
Exact Mass	376.224976
PSA	97.99000
LogP	2.70
Vapour Pressure	0.0±4.0 mmHg at 25°C
Index of Refraction	1.559

Precursor 3
105499-53-4 1415668-74-4 1070971-82-2
DownStream 0

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

872993-05-0	1881277-32-2
528583-91-7	937738-63-1
937738-64-2	916888-47-6
1781227-87-9	578008-43-2
578008-41-0	865532-70-3
899728-40-6	886951-49-1
899991-83-4	899959-69-4
899993-39-6	886956-17-8
898617-80-6	898631-01-1
886958-12-9	886962-72-7